# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Matt McGinley reiterates BRC (NYSE:BRCC) with a Hold.
Roth MKM analyst George Kelly reiterates BRC (NYSE:BRCC) with a Buy and raises the price target from $6 to $7.
Telsey Advisory Group analyst Sarang Vora maintains BRC (NYSE:BRCC) with a Outperform and maintains $8 price target.
BRC (NYSE:BRCC) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.03) by 133.33 p...
Telsey Advisory Group analyst Sarang Vora reiterates BRC (NYSE:BRCC) with a Outperform and maintains $8 price target.
U.S. stock futures were mixed this morning, with the Dow futures falling by around 10 points on Monday.
Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today’s pre-market trading after the company ...